Top Suppliers:I want be here
Related CAS#:
69655-05-6 134892-26-5
124516-24-1 130676-58-3
142894-15-3 142894-17-5
117525-25-4 810694-79-2
130676-57-2 142504-05-0
2229218-94-2 2228484-98-6
2227813-41-2 2229578-30-5
2228512-98-7 2228282-21-9
2229016-58-2 2228990-14-3
2229578-40-7 2227687-92-3

69655-05-6

69655-05-6 structure
69655-05-6 structure
  • Name: 2',3'-Dideoxyinosine
  • Chemical Name: didanosine
  • CAS Number: 69655-05-6
  • Molecular Formula: C10H12N4O3
  • Molecular Weight: 236.227
  • Catalog: API Synthetic anti-infective drugs Antiviral drugs
  • Create Date: 2018-04-01 08:00:00
  • Modify Date: 2025-08-21 22:28:41
  • Didanosine(Videx) is a reverse transcriptase inhibitor with an IC50 of 0.49 μM.Target: NRTIs; HIVDidanosine is a dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Didanosine demonstrated linear pharmacokinetic behavior over the dose ranges of 0.4 to 16.5 mg/kg intravenously and 0.8 to 10.2 mg/kg orally. Bioavailability of didanosine when administered as a solution with an antacid was approximately 43% for doses from 0.8 to 10.2 mg/kg in patients with AIDS and advanced AIDS-related complex. Bioavailability of didanosine from the citrate-phosphate-buffered solution, the formulation currently used in phase II and expanded access studies, was comparable to the formulation used in the phase I trials [1]. ddI might be responsible for fulminant hepatitis in all three AIDS patients. This toxic effect may be added to the list of potential adverse events occurring during ddI therapy [2].
Name didanosine
Synonyms 9-[(2R,5S)-5-(hydroxyméthyl)tétrahydrofuran-2-yl]-1,9-dihydro-6H-purin-6-one
DDI
Videx
9-[(2R,5S)-5-(Hydroxymethyl)tetrahydro-2-furanyl]-1,9-dihydro-6H-purin-6-one
9-[(2R,5S)-5-(Hydroxymethyl)tetrahydrofuran-2-yl]-9H-purin-6-ol
MFCD00077728
Inosine, 2’,3’-dideoxy-
VIDEX EC
2',3'-Dideoxyinosine
9-[(2R,5S)-5-(Hydroxymethyl)tetrahydrofuran-2-yl]-1,9-dihydro-6H-purin-6-one
6H-Purin-6-one, 1,9-dihydro-9-[(2R,5S)-tetrahydro-5-(hydroxymethyl)-2-furanyl]-
INOSINE, 2',3'-DIDEOXY-
Dideoxyinosine
Didanosine
9-[(2R,5S)-5-(Hydroxymethyl)tetrahydrofuran-2-yl]-1,9-dihydro-6H-purin-6-on
didanosinum [INN_la]
Description Didanosine(Videx) is a reverse transcriptase inhibitor with an IC50 of 0.49 μM.Target: NRTIs; HIVDidanosine is a dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Didanosine demonstrated linear pharmacokinetic behavior over the dose ranges of 0.4 to 16.5 mg/kg intravenously and 0.8 to 10.2 mg/kg orally. Bioavailability of didanosine when administered as a solution with an antacid was approximately 43% for doses from 0.8 to 10.2 mg/kg in patients with AIDS and advanced AIDS-related complex. Bioavailability of didanosine from the citrate-phosphate-buffered solution, the formulation currently used in phase II and expanded access studies, was comparable to the formulation used in the phase I trials [1]. ddI might be responsible for fulminant hepatitis in all three AIDS patients. This toxic effect may be added to the list of potential adverse events occurring during ddI therapy [2].
Related Catalog
References

[1]. Knupp, C.A., et al., Pharmacokinetics of didanosine in patients with acquired immunodeficiency syndrome or acquired immunodeficiency syndrome-related complex. Clin Pharmacol Ther, 1991. 49(5): p. 523-35.

[2]. Bissuel, F., et al., Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy. J Intern Med, 1994. 235(4): p. 367-71.
Density 1.8±0.1 g/cm3
Boiling Point 531.2±60.0 °C at 760 mmHg
Melting Point 193-195 °C
Molecular Formula C10H12N4O3
Molecular Weight 236.227
Flash Point 275.0±32.9 °C
Exact Mass 236.090942
PSA 93.03000
LogP -1.31
Vapour Pressure 0.0±1.5 mmHg at 25°C
Index of Refraction 1.798
Storage condition 2-8°C
Stability Stable. Combustible. Incompatible with strong oxidizing agents.
Water Solubility 1-5 g/100 mL at 21 ºC

CHEMICAL IDENTIFICATION

RTECS NUMBER :
NM7460700
CHEMICAL NAME :
Inosine, 2',3'-dideoxy-
CAS REGISTRY NUMBER :
69655-05-6
LAST UPDATED :
199803
DATA ITEMS CITED :
7
MOLECULAR FORMULA :
C10-H12-N4-O3
MOLECULAR WEIGHT :
236.26

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - man
DOSE/DURATION :
2340 mg/kg/34W-I
TOXIC EFFECTS :
Liver - fatty liver degeneration Liver - jaundice, cholestatic Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - transaminases
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
>2 gm/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
>2 gm/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
>2 gm/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
28 gm/kg/28D-I
TOXIC EFFECTS :
Immunological Including Allergic - decrease in humoral immune response

MUTATION DATA

TEST SYSTEM :
Rodent - mouse
DOSE/DURATION :
6 gm/kg/3D (Intermittent)
REFERENCE :
EMMUEG Environmental and Molecular Mutagenesis. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.10- 1987- Volume(issue)/page/year: 18,168,1991
Personal Protective Equipment Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter
Hazard Codes C
Risk Phrases R34
Safety Phrases S26-S27-S36/37/39-S45
RIDADR NONH for all modes of transport
WGK Germany 2
RTECS NM7460700
HS Code 2942000000
HS Code 2942000000
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.

Chemsrc provides CAS#:69655-05-6 MSDS, density, melting point, boiling point, structure, formula, molecular weight, synthetic route, etc.
title: CAS No. 69655-05-6 | Chemsrc address: https://www.chemsrc.com/en/baike/1192726.html

Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer

Copyright © 2024 ChemSrc All Rights Reserved